دورية أكاديمية
أعرض في EDS

The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort.

التفاصيل البيبلوغرافية
العنوان: The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort.
المؤلفون: Saxby K; Centre for Health Economics, Monash Business School, Monash University, Victoria., Nickson C; Cancer Research Unit, Cancer Council NSW, New South Wales.; Melbourne School of Population and Global Health, University of Melbourne, Victoria.; School of Public Health, The University of Sydney, New South Wales., Mann GB; The Breast Service, Royal Melbourne and Royal Women's Hospital, Victoria.; Department of Surgery, The University of Melbourne, Victoria., Velentzis L; Cancer Research Unit, Cancer Council NSW, New South Wales.; Melbourne School of Population and Global Health, University of Melbourne, Victoria.; School of Public Health, The University of Sydney, New South Wales., Bromley HL; Health Economics Unit, University of Birmingham, UK.; Melbourne School of Population and Global Health, University of Melbourne, Victoria., Procopio P; Cancer Research Unit, Cancer Council NSW, New South Wales.; Melbourne School of Population and Global Health, University of Melbourne, Victoria.; School of Public Health, The University of Sydney, New South Wales., Canfell K; Cancer Research Unit, Cancer Council NSW, New South Wales.; School of Public Health, The University of Sydney, New South Wales., Petrie D; Centre for Health Economics, Monash Business School, Monash University, Victoria.
المصدر: Australian and New Zealand journal of public health [Aust N Z J Public Health] 2020 Jun; Vol. 44 (3), pp. 219-226. Date of Electronic Publication: 2020 Apr 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9611095 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1753-6405 (Electronic) Linking ISSN: 13260200 NLM ISO Abbreviation: Aust N Z J Public Health Subsets: MEDLINE
أسماء مطبوعة: Publication: 2023- : [New York] : Elsevier
Original Publication: Canberra, ACT : Public Health Association of Australia, [1996-
مواضيع طبية MeSH: Breast Neoplasms/*diagnosis , Carcinoma, Intraductal, Noninfiltrating/*diagnosis , Early Detection of Cancer/*economics , Health Care Costs/*statistics & numerical data , Health Services/*statistics & numerical data , Mammography/*economics , Mass Screening/*economics, Adult ; Aged ; Australia/epidemiology ; Breast Neoplasms/epidemiology ; Carcinoma, Intraductal, Noninfiltrating/epidemiology ; Cohort Studies ; Female ; Health Services/economics ; Humans ; Middle Aged ; Neoplasm Staging ; Registries
مستخلص: Objective: To determine the government and out-of-pocket community costs (out-of-hospital medical services and prescription medicines) associated with screen-detected and community-detected cancers (i.e. cancers detected outside of Australia's organised screening program [BreastScreen]).
Methods: We analyse administrative data on government-subsidised medical services and prescription medicines for 568 Victorian women diagnosed with breast cancer or ductal carcinoma in situ (DCIS). Using multivariable regression analysis, we estimate the government and out-of-pocket community costs incurred in the three years after diagnosis for screen-detected cancers and community-detected cancers. Additionally, we estimate the government costs associated with diagnosis within and outside of BreastScreen.
Results: Average government costs for breast cancer diagnosis were similar within and outside of BreastScreen [$808 (lower limit 676; upper limit 940) vs $837 (95%CI 671; 1,003) respectively]; however, women with community-detected cancers incurred an additional $254 (95%CI 175; 332) out-of-pocket. Controlling for differences in known cancer characteristics, compared to screen-detected cancers, community-detected breast cancers were associated with an additional $2,622 (95%CI 644; 4,776) in government expenditure in the three years following diagnosis. Adverse cancer characteristics that were more prevalent in community-detected cancers (high grade, lymph node involvement, HER2 positive receptor status) were associated with increased government and out-of-pocket costs.
Conclusions: Community-detected breast cancers were associated with increased government and out-of-pocket costs. Implications for public health: These costs should be considered when evaluating current and alternative breast cancer screening strategies.
(© 2020 The Authors.)
References: Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43-6.
Department of Health and Ageing. Evaluation of the BreastScreen Australia Program-Evaluation Final Report. Canberra (AUST): AGPS; 2009.
Butler JR, Furnival CM, Hart RF. The costs of treating breast cancer in Australia and the implications for breast cancer screening. Aust N Z J Surg. 1995;65(7):485-91.
Salkeld G, Gerard K. Will early detection of breast cancer reduce the costs of treatment? Aust J Public Health. 1994;18(4):388-93.
Kauhava L, Immonen-Raiha P, Parvinen I, Helenius H, Kaljonen A, Rasanen O, et al. Lower costs of hospital treatment of breast cancer through a population-based mammography screening programme. Eur J Public Health. 2004;14(2):128-33.
Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment: A 4-year longitudinal study. Arch Intern Med. 1996;156(19):2197-201.
Carter SM, Rogers W, Heath I, Degeling C, Doust J, Barratt A. The challenge of overdiagnosis begins with its definition. BMJ. 2015;350:h869.
BreastScreen Australia Evaluation Advisory Committee. BreastScreen Australia Evaluation: Evaluation Final Report. Screening Monograph. Melbourne (AUST): Breast Cancer Network Australia; 2009.
Harris A, Bulfone L. Getting value for money: The Australian experience. Health care Coverage Determinations: An International Comparative Study. 2 In: Jost TS, editor. Health Care Coverage Determinations: An International Comparative Study. Maidenhead (UK): Open University Press; 2004. p. 25-56.
Australian Pharmaceutical Benefits Scheme. Fees, Patient Contributions and Safety Net Thresholds. Canberra (AUST): Australian Department of Health; 2018.
Department of Health. The July 2018 Medicare Benefits Schedule. Canberra (AUST): Government of Australia; 2018.
BreastScreen Victoria. Reports and Statistics. Melbourne (AUST): Breast Screen; 2017.
Australian Intstitute of Health and Welfare. BreastScreen Australia Monitoring Report. Canberra (AUST): AIHW; 2018.
Elder K, Nickson C, Pattanasri M, Cooke S, Machalek D, Rose A, et al. Treatment Intensity Differences After Early-Stage Breast Cancer (ESBC) Diagnosis Depending on Participation in a Screening Program. Ann Surg Oncol. 2018;25(9):2563-72.
Saxby K, Nickson C, Mann B, Elder K, Bromley H, Velentzis L, et al. Treatment patterns and treatment-related morbidity in women with early stage invasive breast cancers detected within and outside of screening. Unpublished Observations.
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi7-23.
Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084-93.
Lord SJ, Marinovich ML, Patterson JA, Wilcken N, Kiely BE, Gebski V, et al. Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Med J Aust. 2012;196(11):688-92.
Earl HM, Hiller L, Vallier A-L, Loi S, Howe D, Higgins HB, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol. 2018;36(15 suppl):506.
Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319-25.
Gordon LG, Elliott TM, Olsen CM, Pandeya N, Whiteman DC. Out-of-pocket medical expenses for Queenslanders with a major cancer. Med J Aust. 2018;208(11):1.
Gordon L, Scuffham P, Hayes S, Newman B. Exploring the economic impact of breast cancers during the 18 months following diagnosis. Psychooncology. 2007;16(12):1130-9.
معلومات مُعتمدة: 1066771 Cancer Australia National Priority Grant
فهرسة مساهمة: Keywords: breast cancer; costs; healthcare use; out-of-pocket; screening
تواريخ الأحداث: Date Created: 20200421 Date Completed: 20200724 Latest Revision: 20200724
رمز التحديث: 20240628
DOI: 10.1111/1753-6405.12976
PMID: 32311194
قاعدة البيانات: MEDLINE
الوصف
تدمد:1753-6405
DOI:10.1111/1753-6405.12976